MRK: Uncover the Latest Merck Stock Movements! Report date: 30 Aug 2026 (all $ = USD)
Could you be due an Irish passport? (1 in 10 Americans might be)
Get the step-by-step guide to claiming an Irish passport and a free copy of European Living shipped to you.
──────────────────────────────────────── 1. Snapshot of the Equity • Last close (28 Aug 2026): $148.35; market-cap ≈ $366 B. GAAP TTM EPS is only $1.25, so the headline P/E screens at 118.7×. • Forward‐looking consensus (Street) P/E runs ~18×—a premium to Pfizer (~10×) and Bristol-Myers (~11×).(finance.yahoo.com) • 52-week range: $79 – $153 (record high set 26 Aug 2026 after positive mRNA cancer-vaccine data; source: Yahoo Finance headline).(finance.yahoo.com)
──────────────────────────────────────── 2. Dividend Policy, History & Yield • Quarterly dividend now $0.85 per share; annualized $3.40. Next ex-date: 15 Sep 2026.(stockanalysis.com) • Forward yield: 2.29 %. Payout ratio on GAAP earnings is optically high (≈ 267 %) owing to acquisition-related amortization; cash payout on non-GAAP earnings and FCF is ~45 %.(stockanalysis.com) • Double-digit dividend growth was paused during the COVID period, but CAGR since 2011 is ~5 %; 15 consecutive annual raises keep Merck in the “Dividend Contenders” cohort.(stockanalysis.com) • Shareholder yield (dividends + buybacks) currently 4.2 %.(stockanalysis.com)
The Biggest Gold Surge in History Is Starting Now
Smart money is already moving. Learn the backdoor gold plays insiders are loading up on — with potential returns that once hit 1,900%.
──────────────────────────────────────── 3. Balance-sheet Leverage, Maturities & Coverage Capital resources (30 Jun 2026 10-Q):(sec.gov) • Gross debt/Total liabilities + equity: 41.5 % vs 36.0 % at YE-25 (debt up after two acquisitions). • Cash & investments: $8.4 B; Working capital: $8.9 B. • Interest expense 1H-26: $1.0 B; cash from ops 1H-26: $9.3 B ⇒ cash-interest-coverage ≈ 9×.(sec.gov)
Key 2026 activity / maturity schedule:(sec.gov) • Jan–Feb 2026: repaid $1.1 B of notes/debentures. • Apr 2026: drew $6 B 364-day term loan (Terns Tx); fully repaid by Jun. • May 2026: issued $6 B senior notes—laddered 2028–2056 (4.30 %–5.85 %). • Next bullet maturity: 1.875 % notes 2026 ($1 B) in Q4.(sec.gov)
Net leverage (ND/EBITDA) pro-forma 2026E ≈ 1.5 ×; S&P/ Moody’s ratings remain A+/A1 (stable). No covenant concerns flagged in filings.
──────────────────────────────────────── 4. Valuation Multiples (at $148.35 share price): • EV/EBITDA (LTM): 14.3 × vs Big-Pharma peer group median ~12 ×.(stockanalysis.com) • EV/FCF: 25.7 × (reflects heavy R&D and deal cash outs this year).(stockanalysis.com) • P/S (2026E): 6.0 ×—rich relative to Pfizer (3.4 ×) but justified by superior oncology growth (Keytruda +12 % y/y Q2).(finance.yahoo.com)
──────────────────────────────────────── 5. Risks, Red Flags & What to Monitor Patent-cliff concentration • Keytruda is >45 % of revenue; its main US patent expires in 2028, with LOE in Europe 2031.(statnews.com) • Sub-cutaneous and combo formulations may extend value, but biosimilar entry risk remains. Investors should track litigation outcomes and FDA/EMA exclusivity extensions.
Deal & leverage execution • Two sizable 2026 acquisitions (Cidara, Terns) financed partly with short-term debt—needs integration and pipeline delivery. • GAAP earnings distortion (amortization) inflates P/E and payout ratios—watch for “adjusted” vs “core” debates.
Policy / IRA exposure • Keytruda expected to enter US Medicare price-setting process in 2026.(fiercepharma.com)
Pipeline & trial risk • Moderna mRNA personalized cancer vaccine (mRNA-4157) in Phase 3. Any delay could leave a post-Keytruda revenue gap.
──────────────────────────────────────── 6. Open Questions for Further Due-diligence 1. Can Merck convert its 364-day facility into a longer-term revolver to preserve balance-sheet flexibility ahead of more BD? 2. How aggressively will Merck repurchase stock once cash balances rebuild—will it offset dilution from recent option exercises? 3. What is management’s updated free-cash-flow guidance (2027–30) under different Keytruda LOE scenarios? 4. Could sub-cutaneous Keytruda or combo intellectual-property push US exclusivity beyond 2028—and is the market discounting that probability?
──────────────────────────────────────── Key Sources (ordered by section) • SEC Form 10-Q 2Q-26 (filed 7 Aug 2026) – liquidity, debt, cash-flow tables, new note issuance.(sec.gov) • StockAnalysis.com – dividend table, yield & shareholder-return metrics; valuation ratios.(stockanalysis.com) • Web finance tool – live quote, market-cap, GAAP EPS & P/E. • Yahoo/Finance News snippet quoting relative forward P/E.(finance.yahoo.com) • STAT & FiercePharma articles on Keytruda patent expiry & LOE strategy.(statnews.com)
(Inline citations appear throughout; hover to view underlying document IDs.)
For informational purposes only; not investment advice.